TD Asset Management Inc. Sells 7,989 Shares of argenx SE (NASDAQ:ARGX)

TD Asset Management Inc. lessened its holdings in shares of argenx SE (NASDAQ:ARGX) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 172,681 shares of the company’s stock after selling 7,989 shares during the period. TD Asset Management Inc. owned about 0.28% of argenx worth $106,199,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. EFG Asset Management North America Corp. grew its position in argenx by 3.1% in the 4th quarter. EFG Asset Management North America Corp. now owns 14,524 shares of the company’s stock valued at $8,942,000 after acquiring an additional 440 shares during the last quarter. LPL Financial LLC lifted its position in shares of argenx by 113.4% during the fourth quarter. LPL Financial LLC now owns 16,317 shares of the company’s stock worth $10,035,000 after purchasing an additional 8,671 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of argenx during the fourth quarter valued at $728,000. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of argenx by 78.6% in the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 75 shares of the company’s stock worth $46,000 after purchasing an additional 33 shares during the last quarter. Finally, iA Global Asset Management Inc. increased its stake in argenx by 5.0% in the 4th quarter. iA Global Asset Management Inc. now owns 5,640 shares of the company’s stock worth $3,469,000 after buying an additional 270 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Trading Down 0.4 %

NASDAQ ARGX opened at $605.52 on Wednesday. The firm’s fifty day simple moving average is $632.24 and its two-hundred day simple moving average is $601.12. The firm has a market capitalization of $36.79 billion, a P/E ratio of -688.09 and a beta of 0.59. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, February 27th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. As a group, sell-side analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ARGX. William Blair reissued an “outperform” rating on shares of argenx in a research report on Friday, February 28th. Oppenheimer increased their price objective on argenx from $675.00 to $704.00 and gave the stock an “outperform” rating in a research note on Friday, February 28th. Guggenheim lifted their target price on argenx from $775.00 to $1,100.00 and gave the company a “buy” rating in a research report on Monday, March 10th. Robert W. Baird increased their price target on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. Finally, Citigroup restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.